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Hossein Poustchi and colleagues1 
reported SARS-CoV-2 antibody 
seroprevalence in the general 
population and high-risk occupational 
groups across 18 cities in Iran. 
However, there are several major 
concerns regarding their study design, 
analysis, and results.
First, although appendix 2 of the 
Article mentions cities as clusters, 
it is unclear how these clusters 
were selected. The inverse of the 
selection probability of individuals, 
which is a function of probability of 
cluster selection and unknown here, 
should be used as weights in the 
analyses.2
Second, the sample size calculation 
has errors. In the design effect formula, 
n is calculated as ∑m2 / ∑m = 1180·2 
(where m is the cluster size)3 but not 
the number of clusters (n=18), as 
mentioned in appendix 2. Also, the 
intracluster correlation (δ) of 0·05 is 
too high for large clusters (such as 
those encountered in the study by 
Poustchi and colleagues), without any 
supporting references. Furthermore, it 
is unclear whether the seroprevalence 
(p) of 0·15 refers to the general 
population or high-risk groups, and 
again no references are given on the 
reported value.
Third, the bootstrap procedure 
described in appendix 2 mimics 
simple random sampling and does 
not consider clustering in the design, 
leading to too narrow confidence 
intervals (CIs). In fact, the appropriate 
bootstrapping procedure for cluster 
designs would draw the cluster 
units rather than individual units 
with replacement. Alternatively, 
one can use cluster-robust standard 
errors.4 The CIs are also narrow due 
to uncertainties in the sensitivity and 
specificity estimates. A Monte-Carlo 
bias analysis from an appropriate 
probability distribution of sensitivity 
and specificity can be used for 
overcoming this problem.5
Fourth, a seroprevalence of 
72·6% for Rasht city seems to be an 
overestimate and inconsistent with 
corroborate the results by Poustchi 
and colleagues (appendix p 1), with 
an overall significant correlation 
(R²=0·67 and p<0·001; appendix 
p 2). Our results further suggest that 
most provinces would continue to 
have a two to four times increase in 
exposure until the end of summer 
(Sept 21, 2020), with Qom and 
Golestan reaching approximately 57% 
(95% CI 44–69) population-level 
exposure.3
In the absence of more recent 
serology or province-level data, 
our estimates provide the most 
recent indicator of prevalence. 
This comparison is of immediate 
epidemiological importance as it 
highlights areas with the largest 
epidemic growth, which require the 
most immediate interventions. The 
continued availability of province-
level data would be of paramount 
public health importance in a country 
that is facing such a heavy toll from 
COVID-19.
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has been the fact that Iran’s Ministry 
of Health and Medical Education 
(MoHME) stopped releasing province-
level data on the number of confirmed 
COVID-19 cases from March 22, 2020, 
onward. Furthermore, provincial 
data on the number of confirmed 
COVID-19-related deaths were never 
released. Instead, MoHME reports the 
percentage change in the number of 
cases with respect to previous days 
as an indicator of the state of the 
epidemic in each province and colour-
codes them from blue (low incidence) 
to yellow (medium incidence), orange 
(high incidence), and red (very high 
incidence).
Despite the significant implications 
of understanding the Iranian 
epidemic for the country and the 
Eastern Mediterranean region as 
a whole, research investigations 
have largely been hindered due to 
the lack of epidemiological data on 
the number of cases and deaths, 
age-stratified and sex-stratified data, 
both at the national and province 
level, and seroepidemiological 
analysis.1 The study by Hossein 
Poustchi and colleagues,2 sponsored 
by MoHME and carried out by the 
then Deputy Minister of Research 
and Technology of the Ministry of 
Health Reza Malekzadeh and his team, 
to measure SARS-CoV-2 antibody 
seroprevalence in the general 
population across 18 cities of Iran 
was the first systematic investigation 
into the geographical spread of 
COVID-19 across the country nearly 
a year after the first two cases were 
reported in Qom on Feb 19, 2020. 
Their analysis showed greatly varied 
levels of exposure in different cities, 
with some reaching very high levels 
(>50% in Qom and Rasht) by late April 
to early June.
Before the study by Poustchi 
and colleagues, we did a similar 
province-level  analysis  using 
seasonal all-cause mortality data 
to estimate the excess mortality in 
all 31 provinces of Iran from winter 
to summer, 2020.3 Our findings 
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Conversely, Nazemipour and co-
lleagues stated that our seroprevalence 
for Rasht was overestimated.2,4 Their 
argument was mainly based on the 
reported seroprevalence of 23·7% in 
Gilan province in a study by Shakiba 
and colleagues4—a study with several 
limitations, including a low participant 
response rate (31·0%) and inadequate 
information on test characteristics. 
Although the test-adjusted estimate for 
Rasht in our study was high, its crude 
estimate was 58·6%, representing the 
effect of test characteristics on assessed 
prevalence (ie, higher prevalence and 
lower test sensitivity would result in a 
higher adjusted estimate). The observed 
variation in adjusted seroprevalence 
estimates between different studies 
is partly related to differences in test 
characteristics. Hence, in addition to 
test sensitivity and specificity, providing 
their CIs could indicate the expected 
variation in a prevalence estimate. In 
Shakiba and colleagues’ study, the CIs 
for VivaDiag test performance were 
not assessed.4 Therefore, the concern 
raised by Nazemipour and colleagues 
that the seroprevalence for Rasht was 
overestimated and inconsistent with 
other studies is neither supported by our 
data nor by other studies.
Since the incidence of COVID-19 
in Rasht city remained high during 
the past few months, Nazemipour 
and colleagues also stated that our 
reported 72·6% seroprevalence 
estimate for Rasht did not follow 
the presumed threshold for herd 
immunity. We disagree with this 
statement as the current evidence on 
herd immunity and its association 
with antibody status is still lacking, 
and a high level of exposure (ie, 
>50%) is not a sufficient indicator for 
herd immunity against COVID-19.5 
This assumption requires further 
investigation and could adversely 
affect the current applied health 
regulat ions and vaccination 
programmes in the country.
Finally, Nazemipour and colleagues 
highlighted some points with 
respect to our analytical approach, 
5 Shakiba M, Nazemipour M, Salari A, et al. 
Seroprevalence of SARS-CoV-2 in Guilan 
province, Iran, April 2020. Emerg Infect Dis 
2020; published online Dec 21. https://doi.
org/10.3201/eid2702.201960.
6 Ghafari M, Kadivar A, Katzourakis A. 
Excess deaths associated with the Iranian 
COVID-19 epidemic: a province-level analysis. 
medRxiv 2020: published online Dec 8. 
https://doi.org/10.1101/2020.12.07.20245621 
(preprint).
7 Choe PG, Kim K-H, Kang CK, et al. Antibody 
responses 8 months after asymptomatic or 
mild SARS-CoV-2 infection. Emerg Infect Dis 
2020; published online Dec 22. https://doi.
org/10.3201/eid2703.204543.
8 Lumley SF, O’Donnell D, Stoesser NE, et al. 
Antibody status and incidence of SARS-CoV-2 
infection in health care workers. N Engl J Med 
2020; published online Dec 23. https://doi.
org/10.1056/nejmoa2034545.
9 Islamic Republic News Agency. The four cities 
of Gilan turned red and Rasht turned orange. 
Dec 7, 2020. https://bit.ly/2M5TKsm 
(accessed Dec 25, 2020).
10 Omer SB, Yildirim I, Forman HP. Herd immunity 
and implications for SARS-CoV-2 control. JAMA 
2020; 324: 2095–96.
the results of other studies, which 
reported estimates of about 23·7% for 
Rasht and 27·5% for Guilan province 
in April and mid-June, respectively.5,6 
This difference cannot be attributed 
to the different design and analysis 
of those studies. Moreover, a SARS-
CoV-2 seropositive status seems to 
be durable (at least up to 8 months 
after infection)7 and can probably 
protect people from reinfection.8 
The alarming (red) status of Rasht 
during the previous months9 is 
not consistent with Poustchi and 
colleagues’ estimated seroprevalence, 
which is higher than the presumed 
threshold of COVID-19 herd immunity 
(50–67%).10
Finally, as seroepidemiological 
studies can affect decisions related 
to immunisation programmes and 
pandemic control measures, we 
believe that the results of Poustchi 
and colleagues’ study should be more 
carefully interpreted, and we hope for 
studies with more robust design and 
analysis.
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on our study reporting the 
seroprevalence of SARS-CoV-2 
antibodies in 18 cities of Iran.1 Our 
findings of considerable variation in 
seroprevalence rates by city and high 
exposure levels in Rasht and Qom are 
supported by Ghafari and colleagues, 
as they observed similar trends in 
province-level excess mortality rates 
in the same regions.2 These findings 
are consistent with a high incidence of 
COVID-19 in a few cities of northern 
(eg, Rasht in Gilan province) and 
central (eg, Qom in Qom province) 
provinces of Iran (red colour-coded 
regions), as reported by the Ministry 
of Health and Medical Education 
(MoHME) early in the pandemic 
(April–June, 2020).2 Furthermore, 
in the seventh report of MoHME, 
summarising the results of scattered 
seroepidemiological studies in Iran, 
among blood donors the prevalence 
of anti-SARS-CoV-2 antibodies in 
Gilan province was 55·0% (95% CI 
38·0–71·0),3 with CIs that overlap 
with the CIs of our estimate in Rasht 
(72·6%, 95% CI 53·9–92·8).
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